Amicus Therapeutics, Inc. share price logo

Amicus Therapeutics, Inc. Share Price

NASDAQ: FOLD

Mid Cap

$14.29

(+-0.03%)

as on

Amicus Therapeutics, Inc. Stock Performance

as on February 3, 2026 at 2:29 am IST

  • Day's Low

    Day's High

    $14.28
    $14.30
    downward going graph

    0.07%

    Downside

    0.07%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.51
    $14.38
    downward going graph

    61.44%

    Downside

    0.63%

    Upside

    downward going graph

Amicus Therapeutics, Inc. share price movements today

Previous Close
$14.29
Open
$14.29
Volume
7.8M
Day's Low - High
$14.28 - $14.30
52 Week Low - High
$5.51 - $14.38

Amicus Therapeutics, Inc. Historical Returns

1 Month Return
+ 0.14 %
3 Month Return
+ 58.25 %
1 Year Return
+ 49.16 %
3 Year Return
+ 5.77 %
5 Year Return
-29.01 %

Amicus Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Amicus Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.5B

EPS (TTM)

0.3784

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-28.04

Industry PE ratio

7.977787610619469

PEG Ratio

-0.18

EBITDA

42.1M

Revenue (TTM)

598.7M

Profit Margin

-2.35%

Return On Equity TTM

-6.87%

Amicus Therapeutics, Inc. Stock Valuation

Track how Amicus Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Amicus Therapeutics, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-74.24x)

December 31, 2024

Today (-28.04x)

February 2, 2026

Industry (7.98x)

February 2, 2026

Highest (185.08x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -28.04x

Amicus Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Amicus Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Amicus Therapeutics, Inc. image
Amicus Therapeutics, Inc.
BUY$4.5B-29.01%-28.04-2.35%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$122.3B116.21%33.5631.35%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$47.7B119.45%1246.031.36%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$37.4BNA662.331.38%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.8B48.3%18.2832.13%

Stock Returns calculator for Amicus Therapeutics, Inc. Stock including INR - Dollar returns

The Amicus Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Amicus Therapeutics, Inc. investment value today

Current value as on today

₹1,54,358

Returns

₹54,358

(+54.36%)

Returns from Amicus Therapeutics, Inc. Stock

₹49,165 (+49.16%)

Dollar Returns*

₹5,193 (+5.19%)

Analyst Recommendation on Amicus Therapeutics, Inc. Stock

Based on 17 analysts

BUY

76.47%

Buy

23.53%

Hold

0.00%

Sell

Based on 17 analysts, 76.47% of analysts recommend a 'BUY' rating for Amicus Therapeutics, Inc.. Average target price of $14.5

Amicus Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Amicus Therapeutics, Inc..

What analysts predicted

1.45%UPSIDE

Target Price

$14.5

Current Price

$14.29

Analyzed by

17 Analysts

Target

$14.50

Amicus Therapeutics, Inc. target price $14.5, a slight upside of 1.45% compared to current price of $14.29. According to 17 analysts rating.

Amicus Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Amicus Therapeutics, Inc. Stock has decreased by -45% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-45% versus previous 30 day period

Amicus Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
94
103
115
110
126
141
149
125
154
169
Gross Profit
85
93
103
96
115
128
134
113
139
147
Operating Income
-18
-17
-3
-27
14
21
15
-7
-9
34
EBITDA
-25
-9
-16
-28
14
21
21
-4
-5
47
Interest Expense
12
12
12
12
12
12
11
11
11
11
Depreciation
2
2
2
2
2
2
2
1
1
1
Income Before Tax
-40
-24
-31
-43
0
6
7
-18
-19
34
Income Tax Expense
2
-3
2
4
15
13
-6
3
5
16
Net Income
-43
-21
-33
-48
-15
-6
14
-21
-24
17
Net Profit Margin
-45.75%
-20.85%
-29.41%
-43.86%
-12.39%
-4.75%
9.85%
-17.31%
-15.79%
10.24%

Amicus Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
4
36
91
182
260
305
329
399
528
Gross Profit
-1
4
30
76
160
229
271
290
362
475
Operating Income
-130
-181
-441
-328
-304
-246
-206
-212
-77
24
EBITDA
-128
-195
-428
-322
-332
-242
-202
-199
-92
29
Interest Expense
1
5
17
22
18
22
32
37
50
49
Depreciation
-
-
3
4
4
8
6
5
7
8
Income Before Tax
-132
-203
-449
-349
-355
-274
-241
-242
-150
-28
Income Tax Expense
1
-3
-165
0
0
2
8
-5
1
27
Net Income
-132
-200
-284
-348
-356
-276
-250
-236
-151
-56
Net Profit Margin
0.00%
-4034.73%
-769.03%
-382.48%
-195.56%
-106.12%
-81.98%
-71.85%
-37.96%
-10.62%

Amicus Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-21
-33
-48
-15
-6
14
-21
-24
17
Operating Cash Flow
-38
3
-29
22
-22
-3
7
-26
35
Investing Cash Flow
35
-23
7
-21
34
-20
-32
-5
-1
Financing Cash Flow
37
8
-13
0
18
1
-11
0
-1
Change in Cash
51
-16
-37
0
24
-20
-31
-22
31

Amicus Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-200
-284
-348
-356
-276
-250
-236
-151
-56
Operating Cash Flow
-150
-215
-299
-250
-233
-202
-166
-69
-33
Investing Cash Flow
-4
-171
-121
95
-13
78
92
98
0
Financing Cash Flow
272
247
450
217
262
212
-7
61
5
Change in Cash
117
-137
31
63
19
83
-96
96
-33

Global Institutional Holdings in Amicus Therapeutics, Inc.

Funds
Holdings
Wellington Management Company LLP
9.45%
Geode Capital Management, LLC
2.19%
Palo Alto Investors, LLC
1.82%
Bank of America Corp
1.82%
Massachusetts Financial Services Company
1.21%
See all

Amicus Therapeutics, Inc. News & Key Events

    Insights on Amicus Therapeutics, Inc.

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 3 months, FOLD stock has moved up by 61.3%

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 2 quarters, -24.42M → 17.30M (in $), with an average increase of 241.1% per quarter

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 3 quarters, 125.24M → 169.06M (in $), with an average increase of 13.8% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Beone Medicines Ltd has given 52.4% return, outperforming this stock by 4.2%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.5% return, outperforming this stock by 24.7%

    About Amicus Therapeutics, Inc.

    amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
    OrganisationAmicus Therapeutics, Inc.
    Headquarters47 Hulfish Street, Princeton, NJ, United States, 08542
    IndustryHealth Technology
    CEOMr. Bradley L. Campbell M.B.A.
    E-voting on sharesClick here to vote

    Key Management of Amicus Therapeutics, Inc.

    Name

    Title

    Ms. Ellen S. Rosenberg J.D.

    Chief Legal Officer & Corporate Secretary

    Dr. Jill Weimer Ph.D.

    Chief Science Officer

    Mr. Andrew Faughnan

    Vice President of Investor Relations

    Mr. Patrik S. Florencio Esq.

    Global Chief Compliance & Risk Officer

    Mr. Bradley L. Campbell M.B.A.

    CEO, President & Director

    Mr. David M. Clark

    Chief People Officer

    Dr. Jeffrey P. Castelli Ph.D.

    Chief Development Officer

    Ms. Samantha L. Prout

    Chief Accounting Officer & Controller

    Mr. Brendan McEvoy

    Executive Director of External Communications

    Mr. Simon Nicolas Reade Harford

    Chief Financial Officer

    FAQs

    What is Amicus Therapeutics, Inc. share price today?

    Amicus Therapeutics, Inc. share price today is $14.29 as on at the close of the market. Amicus Therapeutics, Inc. share today touched a day high of $14.3 and a low of $14.28.

    What is the 52 week high and 52 week low for Amicus Therapeutics, Inc. share?

    Amicus Therapeutics, Inc. share touched a 52 week high of $14.38 on and a 52 week low of $5.51 on . Amicus Therapeutics, Inc. stock price today i.e. is closed at $14.29,which is 0.63% down from its 52 week high and 159.35% up from its 52 week low.

    What is Amicus Therapeutics, Inc.'s market capitalisation today?

    Amicus Therapeutics, Inc. market capitalisation is $0.00T as on .

    How to invest in Amicus Therapeutics, Inc. Stock (FOLD) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Amicus Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amicus Therapeutics, Inc. Shares that will get you 0.1050 shares as per Amicus Therapeutics, Inc. share price of $14.29 per share as on February 3, 2026 at 2:29 am IST.

    What is the minimum amount required to buy Amicus Therapeutics, Inc. Stock (FOLD) from India?

    Indian investors can start investing in Amicus Therapeutics, Inc. (FOLD) shares with as little as ₹91.486 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹914.86 in Amicus Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Amicus Therapeutics, Inc. share’s latest price of $14.29 as on February 3, 2026 at 2:29 am IST, you will get 0.6998 shares of Amicus Therapeutics, Inc.. Learn more about fractional shares .

    What are the returns that Amicus Therapeutics, Inc. has given to Indian investors in the last 5 years?

    Amicus Therapeutics, Inc. stock has given -29.01% share price returns and 25.75% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?